These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 34383182)

  • 21. Dosimetry of 64Cu-DOTA-AE105, a PET tracer for uPAR imaging.
    Persson M; El Ali HH; Binderup T; Pfeifer A; Madsen J; Rasmussen P; Kjaer A
    Nucl Med Biol; 2014 Mar; 41(3):290-5. PubMed ID: 24533988
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early response monitoring with 18F-FDG PET and cetuximab-F(ab')2-SPECT after radiotherapy of human head and neck squamous cell carcinomas in a mouse model.
    van Dijk LK; Boerman OC; Franssen GM; Lok J; Kaanders JH; Bussink J
    J Nucl Med; 2014 Oct; 55(10):1665-70. PubMed ID: 25236350
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Anti-L1CAM radioimmunotherapy is more effective with the radiolanthanide terbium-161 compared to lutetium-177 in an ovarian cancer model.
    Grünberg J; Lindenblatt D; Dorrer H; Cohrs S; Zhernosekov K; Köster U; Türler A; Fischer E; Schibli R
    Eur J Nucl Med Mol Imaging; 2014 Oct; 41(10):1907-15. PubMed ID: 24859811
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Noninvasive Evaluation of CD20 Expression Using
    Kang L; Li C; Rosenkrans ZT; Engle JW; Wang R; Jiang D; Xu X; Cai W
    J Nucl Med; 2021 Mar; 62(3):372-378. PubMed ID: 32826320
    [TBL] [Abstract][Full Text] [Related]  

  • 25. PET of EGFR antibody distribution in head and neck squamous cell carcinoma models.
    Niu G; Li Z; Xie J; Le QT; Chen X
    J Nucl Med; 2009 Jul; 50(7):1116-23. PubMed ID: 19525473
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Epidermal growth factor receptor-targeted radioimmunotherapy of human head and neck cancer xenografts using 90Y-labeled fully human antibody panitumumab.
    Liu Z; Liu Y; Jia B; Zhao H; Jin X; Li F; Chen X; Wang F
    Mol Cancer Ther; 2010 Aug; 9(8):2297-308. PubMed ID: 20682654
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiolabeled Antibodies Against Müllerian-Inhibiting Substance Receptor, Type II: New Tools for a Theranostic Approach in Ovarian Cancer.
    Deshayes E; Ladjohounlou R; Le Fur P; Pichard A; Lozza C; Boudousq V; Sevestre S; Jarlier M; Kashani R; Koch J; Sosabowski J; Foster J; Chouin N; Bruchertseifer F; Morgenstern A; Kotzki PO; Navarro-Teulon I; Pouget JP
    J Nucl Med; 2018 Aug; 59(8):1234-1242. PubMed ID: 29674421
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Radiolabeled F(ab')
    Bellaye PS; Moreau M; Raguin O; Oudot A; Bernhard C; Vrigneaud JM; Dumont L; Vandroux D; Denat F; Cochet A; Brunotte F; Collin B
    Clin Transl Oncol; 2018 Dec; 20(12):1557-1570. PubMed ID: 29777377
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Immuno-PET Imaging and Radioimmunotherapy of 64Cu-/177Lu-Labeled Anti-EGFR Antibody in Esophageal Squamous Cell Carcinoma Model.
    Song IH; Lee TS; Park YS; Lee JS; Lee BC; Moon BS; An GI; Lee HW; Kim KI; Lee YJ; Kang JH; Lim SM
    J Nucl Med; 2016 Jul; 57(7):1105-11. PubMed ID: 26917708
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Preliminary results of biodistribution and dosimetric analysis of [
    Khawar A; Eppard E; Roesch F; Ahmadzadehfar H; Kürpig S; Meisenheimer M; Gaertner FC; Essler M; Bundschuh RA
    Ann Nucl Med; 2019 Jun; 33(6):404-413. PubMed ID: 30877560
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacokinetics and tumor targeting of 131I-labeled F(ab')2 fragments of the chimeric monoclonal antibody G250: preclinical and clinical pilot studies.
    Brouwers A; Mulders P; Oosterwijk E; Buijs W; Corstens F; Boerman O; Oyen W
    Cancer Biother Radiopharm; 2004 Aug; 19(4):466-77. PubMed ID: 15453961
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Superior localisation and imaging of radiolabelled monoclonal antibody E48 F(ab')2 fragment in xenografts of human squamous cell carcinoma of the head and neck and of the vulva as compared to monoclonal antibody E48 IgG.
    Gerretsen M; Quak JJ; Suh JS; van Walsum M; Meijer CJ; Snow GB; van Dongen GA
    Br J Cancer; 1991 Jan; 63(1):37-44. PubMed ID: 1989663
    [TBL] [Abstract][Full Text] [Related]  

  • 33. In vivo evaluation of pretargeted 64Cu for tumor imaging and therapy.
    Lewis MR; Wang M; Axworthy DB; Theodore LJ; Mallet RW; Fritzberg AR; Welch MJ; Anderson CJ
    J Nucl Med; 2003 Aug; 44(8):1284-92. PubMed ID: 12902420
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploration of a F(ab')
    Milenic DE; Kim YS; Baidoo KE; Wong KJ; Barkley R; Delgado J; Brechbiel MW
    Cancer Biother Radiopharm; 2018 Jun; 33(5):182-193. PubMed ID: 29916748
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Theranostic application of
    Li C; Liu J; Yang X; Yang Q; Huang W; Zhang M; Zhou D; Wang R; Gong J; Miao Q; Kang L; Yang J
    Eur J Nucl Med Mol Imaging; 2022 Dec; 50(1):168-183. PubMed ID: 36063202
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Immuno-PET imaging based radioimmunotherapy in head and neck squamous cell carcinoma model.
    Song IH; Noh Y; Kwon J; Jung JH; Lee BC; Kim KI; Lee YJ; Kang JH; Rhee CS; Lee CH; Lee TS; Choi IJ
    Oncotarget; 2017 Nov; 8(54):92090-92105. PubMed ID: 29190900
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Radiation Nanomedicine for EGFR-Positive Breast Cancer: Panitumumab-Modified Gold Nanoparticles Complexed to the β-Particle-Emitter, (177)Lu.
    Yook S; Cai Z; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2015 Nov; 12(11):3963-72. PubMed ID: 26402157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evaluation of
    Sharma R; Mukherjee A; Kumar A; Sarma HD
    Cancer Biother Radiopharm; 2024 Feb; 39(1):64-74. PubMed ID: 38363819
    [No Abstract]   [Full Text] [Related]  

  • 39. Dual-Receptor-Targeted (DRT) Radiation Nanomedicine Labeled with
    Yook S; Cai Z; Jeong JJ; Lu Y; Winnik MA; Pignol JP; Reilly RM
    Mol Pharm; 2020 Apr; 17(4):1226-1236. PubMed ID: 32022567
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH; van Eerd JE; Frielink C; Oosterwijk E; Oyen WJ; Corstens FH; Boerman OC
    J Nucl Med; 2004 Feb; 45(2):327-37. PubMed ID: 14960657
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.